Prospective study with the aim to investigate the biological relevance of fibrinolysis products and their use as prognostic and therapeutic biomarkers in SIRS and SEPSIS.

Recruiting

• Conditions: A41.9; Sepsis, unspecified

• Registration Number: DRKS00000215
• Lead Sponsor: Klinik für Anästhesiologie, Intensivmedizin und SchmerztherapieKlinikum der J.W.-Goethe Universität

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-08-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Stay at ICU >=48h, positive consent, no active neoplasia (>10 years)

Exclusion Criteria

active Neoplasia, age <18 years, no consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint consists in determining the concentrations of fibrin fragments in patient's blood samples and correlating the levels with the overall survival. The primary endpoint is reached with transfer of the patient from intensive care unit.

Secondary Outcome Measures

Name	Time	Method
The secondary endpoint consists in determining the concentrations of fibrin fragments in patient's blood samples and correlating the levels with the progression of disease from SIRS to SEPSIS. The secondary endpoint is reached at progression from SIRS to SEPSIS.